JPRN-UMIN000009928已完成2 期
ECRIPS: Phase II study of docetaxel, cisplatin and cetuximab (TPE) followed by cetuximab with Concurrent Radiotherapy in Patients with local advanced Squamous cell carcinoma of the Head and Neck (LA-SCCHN). - Phase II study of docetaxel, cisplatin and cetuximab (TPE) followed by cetuximab with Concurrent Radiotherapy in Patients with LA-SCCHN (CSPOR-HN 01: ECRIPS)
CSPOR-HN 01 executive committee0 个研究点目标入组 55 人开始时间: 2013年3月10日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Evidence of distant metastasis. 2) Post-operative RT is intended. 3) Pregnancy or breastfeeding. 4) Prior therapy with Cetuximab or monoclonal antibody. 5) Medical or psychiatric condition that would not permit the subject to complete the trial or informed consent. 6) Uncontrollable diabetes or malignant hypertension or liver failure. 7) History of Pulmonary fibrosis, acute lung injury or interstitial pneumonia. 8) Active infection. Known HIV. 9) Known coronary artery disease, history of myocardial infarction within prior 12 months, uncontrollable arrhythmia, or uncontrollable cardiac failure. 10) Dental treatment with incision and drainage. 11) History of multiple cancers unless free of disease for at least three years. 12) Patient judged inappropriate for this trial by physicians.
研究者
相似试验
招募中
2 期
Phase II trial of docetaxel (T), cisplatin (P) and fluorouracil (5-FU) in the treatment of metastatic penile cancerpatients with metastatic penile cancerJPRN-UMIN000002697Fudan University Shanghai Cancer Center40
已完成
2 期
Phase II study of cisplatin, docetaxel, and irinotecan, followed by gefitinib, gemcitabine and vinorelbine for patients with non-small-cell lung cancer harboring active EGFR gene mutations (OLCSG0704)non-small-cell lung cancerJPRN-UMIN000002095Okayama Lung Cancer Study Group30
已完成
不适用
A phase II trial of cisplatin, docetaxel and bevacizumab followed by maintenance pemetrexed and bevacizumab in metastatic non-small-cell lung cancerJPRN-UMIN000004127Okayama Lung Cancer Study Group40
已完成
2 期
Multicenter phase II study of docetaxel/cisplatin/bevacizumab combination therapy in patients with advanced non-squamous non-small cell lung cancer (TORG1016)JPRN-UMIN000004368Thoracic Oncology Research Group47
进行中（未招募）
不适用
Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity inPatients with Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT study) - B-DOCT studyocally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal JunctionMedDRA version: 12.1Level: PTClassification code 10063916Term: Metastatic gastric cancerMedDRA version: 12.1Level: LLTClassification code 10017758Term: Gastric cancerMedDRA version: 12.1Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerEUCTR2010-022699-30-NLederlands Kanker Instutuut-Antonie van Leeuwenhoek Ziekenhuis